Revance Therapeutics, Inc. (RVNC) Financials

$3.47

south_east
-$0 (0%)
Day's range
$3.47
Day's range
$3.51

RVNC Income statement / Annual

Last year (2023), Revance Therapeutics, Inc.'s total revenue was $234.04 M, an increase of 76.55% from the previous year. In 2023, Revance Therapeutics, Inc.'s net income was -$323.99 M. See Revance Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $234.04 M $132.57 M $77.80 M $15.33 M $413,000.00 $3.73 M $262,000.00 $300,000.00 $300,000.00 $383,000.00
Cost of Revenue $152.16 M $51.67 M $23.41 M $4.77 M $102.86 M $92.50 M $0.00 $0.00 $2.00 M $0.00
Gross Profit $81.88 M $80.90 M $54.39 M $10.56 M -$102.45 M -$88.77 M $262,000.00 $300,000.00 -$1.70 M $383,000.00
Gross Profit Ratio 0.35 0.61 0.7 0.69 -248.06 -23.81 1 1 -5.65 1
Research and Development Expenses $79.41 M $101.29 M $116.26 M $125.80 M $102.86 M $92.50 M $80.36 M $50.38 M $47.53 M $33.39 M
General & Administrative Expenses $38.81 M $4.24 M $28.31 M $149.74 M $62.01 M $53.86 M $37.40 M $29.08 M $25.09 M $19.04 M
Selling & Marketing Expenses $253.42 M $183.10 M $166.42 M $2.10 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $292.24 M $223.93 M $198.82 M $151.85 M $62.01 M $53.86 M $37.40 M $29.08 M $25.09 M $19.04 M
Other Expenses $27.01 M $27.85 M $13.99 M $6.08 M -$303,000.00 -$773,000.00 -$525,000.00 -$535,000.00 -$327,000.00 -$234,000.00
Operating Expenses $398.65 M $353.07 M $329.06 M $283.72 M $164.87 M $146.36 M $117.76 M $79.46 M $72.62 M $52.43 M
Cost And Expenses $550.82 M $404.73 M $352.47 M $288.49 M $164.87 M $146.36 M $117.76 M $79.46 M $72.62 M $52.43 M
Interest Income $13.29 M $4.89 M $337,000.00 $4.32 M $5.53 M $4.02 M $1.41 M $1.17 M $231,000.00 $44,000.00
Interest Expense $19.36 M $16.47 M $6.27 M $15.15 M $0.00 $44,000.00 $457,000.00 $1.08 M $1.19 M $10.67 M
Depreciation & Amortization $13.69 M $33.73 M $19.85 M $10.25 M $2.91 M $1.73 M $1.47 M $1.45 M $2.00 M $2.05 M
EBITDA -$290.64 M -$305.52 M -$255.18 M -$259.31 M -$156.52 M -$137.80 M -$118.66 M -$86.74 M -$70.29 M -$50.00 M
EBITDA Ratio -1.24 -1.82 -3.36 -17.18 -385.54 -37.38 -445.08 -261.74 -241.38 -136.4
Operating Income Ratio -1.35 -2.05 -3.53 -17.82 -398.21 -38.25 -459.63 -294.05 -241.06 -135.9
Total Other Income/Expenses Net -$6.91 M -$13.76 M -$6.63 M -$11.55 M $5.03 M $3.07 M -$163,000.00 -$1.06 M -$1.16 M -$10.87 M
Income Before Tax -$323.69 M -$355.72 M -$281.31 M -$284.71 M -$159.43 M -$139.57 M -$120.59 M -$89.27 M -$73.48 M -$62.92 M
Income Before Tax Ratio -1.38 -2.68 -3.62 -18.58 -386.03 -37.43 -460.26 -297.57 -244.92 -164.27
Income Tax Expense $300,000.00 $700,000.00 $5.51 M -$2.62 M -$3.21 M $3.00 M -$1.54 M -$898,000.00 -$1.13 M $8.39 M
Net Income -$323.99 M -$356.42 M -$286.82 M -$282.09 M -$156.22 M -$142.57 M -$120.59 M -$89.27 M -$73.48 M -$62.92 M
Net Income Ratio -1.38 -2.69 -3.69 -18.41 -378.25 -38.23 -460.26 -297.57 -244.92 -164.27
EPS -3.83 -4.9 -4.25 -4.86 -3.59 -3.94 -4.01 -3.18 -3.02 -3.24
EPS Diluted -3.83 -4.9 -4.25 -4.86 -3.59 -3.94 -4.01 -3.18 -3.02 -3.24
Weighted Average Shares Out $84.60 M $72.71 M $67.51 M $58.01 M $43.46 M $36.17 M $30.10 M $28.11 M $24.33 M $19.39 M
Weighted Average Shares Out Diluted $84.60 M $72.71 M $67.51 M $58.01 M $43.46 M $36.17 M $30.10 M $28.11 M $24.34 M $19.39 M
Link